Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a novel approach to treating multiple sclerosis (MS) by focusing on myelin protection rather than broad immune suppression. The company’s lead drug candidate, Lucid-MS, is designed to prevent and reverse myelin degradation, the underlying mechanism of MS, according to a recent article highlighted by the company.
The rationale for this approach stems from growing evidence that MS disability can progress independently of relapses, a phenomenon known as progression independent of relapse activity (PIRA). The article discusses chronic active, or ‘smoldering,’ lesions and compartmentalized inflammation within the central nervous system as potential contributors to ongoing tissue damage that may not be adequately addressed by current therapies, which primarily target peripheral immune activity.
Lucid-MS takes a different tack by directly targeting myelin degradation, with the goal of preserving myelin and supporting functional recovery. This mechanism could offer a complementary or alternative strategy to existing disease-modifying therapies that focus on reducing immune attacks on the central nervous system.
Quantum BioPharma has collaborated with Massachusetts General Hospital on PET imaging designed to assess myelin integrity, which could be crucial for monitoring treatment effectiveness in clinical trials. The company recently received clearance to begin a Phase 2 trial of Lucid-MS, following Phase 1 studies that reported a favorable safety profile in healthy volunteers.
The potential significance of this approach is underscored by the unmet need in MS treatment. While current therapies can reduce relapse rates and delay disability progression, many patients continue to experience worsening disability despite treatment. By addressing myelin repair and protection, Lucid-MS could potentially slow or even reverse disability accumulation, improving long-term outcomes for patients.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for treating challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation.
In addition to its MS program, Quantum BioPharma has developed UNBUZZD(TM), a product for alcohol misuse, and retains ownership of 19.48% of Unbuzzd Wellness Inc., which markets the over-the-counter version. The agreement includes royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity.
The company’s newsroom provides the latest updates on QNTM: https://ibn.fm/QNTM. The full article discussing the myelin protection approach is available at https://ibn.fm/UPeUg.
